Kyohei Oyama

Dr. Kyohei Oyama

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
BLBruna B. J. Leal
Bruna B. J. Leal
NWNaohiro Wakabayashi
Naohiro Wakabayashi
KOKyohei Oyama
Kyohei Oyama
HKHiroyuki Kamiya
Hiroyuki Kamiya
DBDaikelly I. Braghirolli
Daikelly I. Braghirolli
PPPatricia Pranke
Patricia Pranke
Cardiovascular disease is the most common cause of death in the world. In severe cases, replacement or revascularization using vascular grafts are the treatment options. While several synthetic vascular grafts are clinically used with common approval for medium to large-caliber vessels, autologous vascular grafts are the only options clinically approved for small-caliber revascularizations. Autologous grafts have, however, some limitations in quantity and quality, and cause an invasiveness to patients when harvested. Therefore, the development of small-caliber synthetic vascular grafts (<5 mm) has been urged. Since small-caliber synthetic grafts made from the same materials as middle and large-caliber grafts have poor patency rates due to thrombus formation and intimal hyperplasia within the graft, newly innovative methodologies with vascular tissue engineering such as electrospinning, decellularization, lyophilization, and 3D printing, and novel polymers have been developed. This review article represents topics on the methodologies used in the development of scaffold-based vascular grafts and the polymers usedin vitroandin vivo.

1 August 2018 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
DEDanny El-Nachef
Danny El-Nachef
KOKyohei Oyama
Kyohei Oyama
YWYun-Yu Wu
Yun-Yu Wu
MFMiles Freeman
Miles Freeman
YZYiqiang Zhang
Yiqiang Zhang
WMW. Robb MacLellan
W. Robb MacLellan

7 June 2020 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
PDF file
HIHayato Ise
Hayato Ise
HKHiroto Kitahara
Hiroto Kitahara
KOKyohei Oyama
Kyohei Oyama
KTKeiya Takahashi
Keiya Takahashi
HKHirotsugu Kanda
Hirotsugu Kanda
HKHiroyuki Kamiya
Hiroyuki Kamiya
Objectives: Hypothermic circulatory arrest (HCA) has been considered to cause coagulopathy during cardiac surgery. However, coagulopathy associated with HCA has not been understood clearly in details. The objective of this study is to analyze the details of coagulopathy related to HCA in cardiac surgery by using rotational thromboelastometry (ROTEM). Methods: We retrospectively analyzed 38 patients who underwent elective cardiac surgery (HCA group = 12, non-HCA group = 26) in our hospital. Blood samples were collected before and after cardiopulmonary bypass (CPB). Standard laboratory tests (SLTs) and ROTEM were performed. We performed four ROTEM assays (EXTEM, INTEM, HEPTEM and FIBTEM) and analyzed the following ROTEM parameters: clotting time (CT), clot formation time (CFT), maximum clot firmness (MCF) and maximum clot elasticity (MCE). The amount of perioperative bleeding, intraoperative transfusion and perioperative data were compared between the HCA and non-HCA group. Results: Operation time and hemostatic time were significantly longer in the HCA group, whereas CPB time had no difference between the groups. The amount of perioperative bleeding and intraoperative transfusion were much higher in the HCA group. SLTs showed no difference between the groups both after anesthesia induction and after protamine reversal. In ROTEM analysis, MCE contributed by platelet was reduced in the HCA group, whereas MCE contributed by fibrinogen had no difference. Conclusion: Our study confirmed that the amount of perioperative bleeding and intraoperative transfusion were significantly higher in the HCA group. ROTEM analysis would indicate that clot firmness contributed by platelet component is reduced by HCA in cardiac surgery.

4 November 2014 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
KOKyohei Oyama
Kyohei Oyama
DEDanny El-Nachef
Danny El-Nachef
YZYiqiang Zhang
Yiqiang Zhang
PSPatima Sdek
Patima Sdek
WMW. Robb MacLellan
W. Robb MacLellan
Cardiac myocytes proliferate robustly during fetal life but withdraw permanently from the cell cycle soon after birth and undergo terminal differentiation. This cell cycle exit is associated with upregulation of a host of adult cardiac-specific genes. The vast majority of adult cardiac myocytes do not reenter cell cycle even if subjected to mitogenic stimuli. The basis for this irreversible cell cycle exit is related to stable silencing of cell cycle genes specifically involved in the progression of G2/M transition and cytokinesis. Studies have begun to clarify the molecular basis for this stable gene repression and have identified epigenetic and chromatin structural changes in this process. In this review, we summarize the current understanding of epigenetic regulation of cardiac myocyte cell cycle and cardiac specific gene expression with a focus on histone modifications and the role of retinoblastoma family members.

1 September 2020 in eLife
Verified
Journal Article
Open access
CDCheng Dong
Cheng Dong
RNReiko Nakagawa
Reiko Nakagawa
KOKyohei Oyama
Kyohei Oyama
YYYusuke Yamamoto
Yusuke Yamamoto
WZWeilian Zhang
Weilian Zhang
JMJinrong Min
Jinrong Min
The Polycomb repressive complex 2 (PRC2) is a multicomponent histone H3K27 methyltransferase complex, best known for silencing theHoxgenes during embryonic development. The Polycomb-like proteins PHF1, MTF2, and PHF19 are critical components of PRC2 by stimulating its catalytic activity in embryonic stem cells. The Tudor domains of PHF1/19 have been previously shown to be readers of H3K36me3 in vitro. However, some other studies suggest that PHF1 and PHF19 co-localize with the H3K27me3 mark but not H3K36me3 in cells. Here, we provide further evidence that PHF1 co-localizes with H3t in testis and its Tudor domain preferentially binds to H3tK27me3 over canonical H3K27me3 in vitro. Our complex structures of the Tudor domains of PHF1 and PHF19 with H3tK27me3 shed light on the molecular basis for preferential recognition of H3tK27me3 by PHF1 and PHF19 over canonical H3K27me3, implicating that H3tK27me3 might be a physiological ligand of PHF1/19.

1 January 2011 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
KOKyohei Oyama
Kyohei Oyama
KTKiyoshi Takahashi
Kiyoshi Takahashi
KSKoichi Sakurai
Koichi Sakurai
Cell cycle arrest is associated with differentiation, senescence and apoptosis. We investigated alterations in the cell cycle during the development of hypertrophy induced by hydrogen peroxide (H2O2) in the H9c2 clonal myoblastic cell line. H2O2 induced hypertrophy in H9c2 cells that was indicated by an increase in atrial natriuretic peptide (ANP) gene expression, a marker of cardiomyocyte hypertrophy, and a larger cell size. On induction of hypertrophy by H2O2 in H9c2 cells, cell proliferation was arrested, indicated by the number of cells remaining constant during a 72-h incubation period. The cell cycle was arrested at the G1 and G2/M phases with an increase in p21 expression, a negative cell cycle regulator. Cell cycle arrest and increase in p21 expression were significantly inhibited by 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetra (acetoxymethyl) ester (BAPTA-AM), an intracellular calcium chelator. Although ANP gene expression was induced significantly, H2O2 failed to induce hypertrophy in the presence of BAPTA-AM, and the cell cycle progressed. We concluded that H2O2 induced cell cycle arrest in H9c2 cells, which was related to cellular hypertrophy.